Specialty Pharmaceuticals - Rare and Orphan Diseases
Strategic Profile
Quoin is strategically positioned for near-term value inflection with QRX003 enrollment expected to complete in 1H 2026 and top-line data anticipated in 2H 2026. The company has secured orphan drug designations in the US, EU, and Japan, and is expanding internationally with distribution agreements and regulatory pathways in multiple regions. Diversified pipeline includes topical rapamycin programs for lymphatic and venous malformations targeting unmet needs with no FDA-approved alternatives.
Cyborg Score Rationale
Compelling catalysts with near-term pivotal trial data expected in H2 2026 and regulatory approvals potential as early as late 2026/early 2027. Strong cash position following ~$105M financing and clear path to commercialization. Key risks include trial success uncertainties and commercial execution in ultra-rare disease market.
Top Insights
QRX003 targeting first FDA-approved treatment for unmet rare disease with zero approved alternatives, positioning as potential blockbuster in orphan segment
Multi-jurisdictional regulatory momentum with ODD/Fast Track designations in US, EU, and Japan plus breakthrough designation filing in Saudi Arabia
Expansion beyond lead asset with topical rapamycin platform entering clinical testing 1H 2026 for additional orphan indications
Adequate capitalization through $105.3M private placement enabling runway into 2027 and funding for multiple programs
Named Competitors
Orphan Disease Treatments — Rare disease focused biotech with alternative pipeline
Rare Disease Therapeutics — Specialty pharma with orphan disease portfolio
Topical Skin Therapies — Technology partner for proprietary delivery formulations
Recent Developments
(February 2026) Japan MHLW confirmed ODD and Fast Track designation for QRX003 in Netherton Syndrome; subsidiary establishment planned
(November 2025) Achieved target topical rapamycin loadings for lotion (4%) and dermal patch (5%) formulations; clinical testing planned 1H 2026
(November 2025) Announced private placement financing of up to $105.3M to fund pivotal trials and expanded pipeline
(October 2025) FDA granted Orphan Drug Designation for QRX003 in Netherton Syndrome
Open the full interactive Quoin Pharmaceuticals, Ltd. report
30-page strategic research, 15-min analyst-debate audio briefing, full Cyborg Score breakdown across 11 dimensions.